Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1016 • ACR Convergence 2024
Pharmacoequity of DMARDs Among Adults with Rheumatoid Arthritis in the U.S
Ashkan Ara¹, Matthew Chenoweth², Srikanth Kadiyala², Utibe Essien³ and Christopher Scannell³, ¹Division of Rheumatology, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, ²Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, ³Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles
Background/Purpose: Long-term management of rheumatoid arthritis (RA) relies on disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic (tsDMARDs). About 40%…
Abstract Number: 1077 • ACR Convergence 2024
Pragmatic Quantitative Rheumatologist 0–10 Visual Numeric Scale Estimates of Inflammation, Damage, and Patient Distress Have Face Validity and May Be as Informative as Formal 28 Joint Counts in Rheumatoid Arthritis
Theodore Pincus¹, tengfei Li² and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, washington dc
Background/Purpose: A 28 joint count of swelling (SJC), tenderness/pain on motion (TJC), and deformity/limited motion (DJC), is recommended to assess rheumatoid arthritis (RA) patient status.…
Abstract Number: 1330 • ACR Convergence 2024
Increased Levels of F-calprotectin in Patients with Early Rheumatoid Arthritis at Diagnosis
Jon Einarsson¹, Katarina Friberger Pajalic², Caroline Bengtsson³, Carmen Roseman⁴, Ellen Landgren¹, Elisabeth Mogard⁵, Elisabet Lindqvist⁵, Tor Olofsson⁴, Johan Karlsson Wallman⁶ and Meliha C Kapetanovic⁴, and Lund Arthritis Research Group (LARG), ¹Lund University, Department of Clinical Sciences Lund, section of rheumatology and Skåne University Hospital Lund, Sweden, Lund, Skane Lan, Sweden, ²Lunds University, Department of clinical sciences, section of Rheumatology Malmö and Skåne University Hospital Malmö, Sweden, Malmö, Sweden, ³Skåne University Hospital Lund, Sweden, Lund, Sweden, ⁴Lund University, Department of Clinical Sciences Lund, section of rheumatology and Skåne University Hospital Lund, Sweden, Lund, Sweden, ⁵Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden
Background/Purpose: Alterations in gut microbiota (dysbiosis) may contribute to the development of rheumatoid arthritis (RA). Elevated fecal calprotectin (F-calprotectin), an established biomarker of gut inflammation, has…
Abstract Number: 1346 • ACR Convergence 2024
Early Diagnosis of Rheumatoid Arthritis: Role of Joint Ultrasound Assessment
Cristina Corrales Selaya¹, Carmen Secada Gómez², Sabela Fernandez-Aguado³, Isla Morante-bolado⁴, Montserrat Santos-gomez⁵, Sara Alonso-Castro⁶, Virginia Portilla-González⁷, Ricardo Blanco-Alonso⁸, Javier Rueda Gotor⁴ and alfonso Corrales-Martínez⁹, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario Montecelo, Pontevedra, Galicia, Spain, ⁴Hospital Sierrallana, Torrelavega, Cantabria, Spain, ⁵Hospital universitario Central de Asturias, Oviedo, Asturias, Spain, ⁶Hospital Universitario Central de Asturias., Oviedo, Asturias, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁹Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Early diagnosis of Rheumatoid Arthritis (RA) is essential to establish treatment to improve long-term disease outcomes. Musculoskeletal ultrasound (US) is able to detect subclinical…
Abstract Number: 1362 • ACR Convergence 2024
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Peter C. Taylor¹, Aditi Kadakia², Jack Milligan³, Sander Strengholt², Oliver Howell³, Pankaj Patel², Sophie Barlow³ and Roberto Caporali⁴, ¹University of Oxford, Oxford, United Kingdom, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy
Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…
Abstract Number: 1378 • ACR Convergence 2024
Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis
Marta Hernández-Díaz¹, Iván Ferraz-Amaro², Sergio Santos-Concepción³, Javier Castro³, Vanesa Hernandez⁴, Beatriz Tejera Segura⁵, Cristina Luna⁶, Esmeralda Delgado-Frías² and Federico Diaz-González², ¹Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ²Hospital Universitario de Canarias, La Laguna, Spain, ³Universidad de La Laguna, La Laguna, Spain, ⁴Rheumatology department. Hospital Universitario de Canarias, La Laguna, Spain, ⁵Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ⁶Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz, Spain
Background/Purpose: Tocilizumab (TCZ) is used in diseases characterized by markedly elevated inflammatory markers and elevated pro-inflammatory cytokines like rheumatoid arthritis (RA), juvenile idiopathic arthritis and…
Abstract Number: 1395 • ACR Convergence 2024
Effects of Butyrate Supplementation in Modulation of Gut Microbiome and Its Metabolites in New Onset Rheumatoid Arthritis
Rebecca Blank¹, Alba Boix-Amoros², Erin Reilly³, Kevin Bu⁴, Ian Cunningham⁵, Renuka Nayak⁶, Andrew Patterson⁷, Jose Clemente⁴ and Jose Scher⁸, ¹NYU, New York, NY, ²Icahn School of Medicine, New York, NY, ³Penn State, State Park, PA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶University of California, San Francisco (UCSF), San Francisco, CA, ⁷Penn State University, State College, PA, ⁸New York University School of Medicine, New York, NY
Background/Purpose: The gut microbiome and its metabolites are dysregulated in RA and other immune-mediated inflammatory diseases. However, the significance of this observation and its implications…
Abstract Number: 1663 • ACR Convergence 2024
Notch—mediated Fibrogenic Activation Is a Spatial Determinant of RA Treatment Response
Kartik Bhamidipati¹, Ce Gao¹, Ksenia Anufrieva², Shideh Kazerounian³, Roopa Madhu⁴, Miles Tran¹, Vikram Khedgikar¹, Sonia Presti¹, Anna Helena Jonsson⁵, ilya Korsunsky¹ and Kevin Wei⁶, ¹Brigham and Women's Hospital, Boston, MA, ²BWH, Cambridge, MA, ³Brigham & Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵University of Colorado School of Medicine, Aurora, CO, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: In RA, poor treatment response has been linked to a fibroid synovial tissue phenotype, characterized by lack of immune cell infiltration and an expansion…
Abstract Number: 1745 • ACR Convergence 2024
Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis
Jon Giles¹, christina Charles-Schoeman², Maya H. Buch³, Maxime Dougados⁴, Zoltan Szekanecz⁵, Ted Mikuls⁶, Steven R Ytterberg⁷, Gary G Koch⁸, Kenneth Kwok⁹, Mary Jane Cadatal¹⁰, Sujatha Menon¹¹, Yan Chen¹², Annette M Diehl¹², Jose L Rivas¹³, Arne Yndestad¹⁴ and Deepak L Bhatt¹⁵, ¹Cedars Sinai Medical Center, Los Angeles, CA, ²UCLA Medical Center, Santa Monica, CA, ³Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ⁴Université de Paris; Department of Rheumatology, Hôpital Cochin; Assistance Publique-Hôpitaux de Paris; and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France, ⁵Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁸Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁹Pfizer Inc, New York, NY, ¹⁰Pfizer Inc, Manila, Philippines, ¹¹Pfizer Inc, Groton, CT, ¹²Pfizer Inc, Collegeville, PA, ¹³Pfizer SLU, Madrid, Spain, ¹⁴Pfizer Inc, Oslo, Norway, ¹⁵Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: ORAL Surveillance (NCT02092467; a post-authorization safety study of tofacitinib 5 and 10 mg twice daily [BID] vs TNF inhibitors [TNFi]) found higher incidence of…
Abstract Number: 1877 • ACR Convergence 2024
Trends in Rheumatoid Arthritis Incidence, Prevalence, DALY and Death Rates (1991-2021) in the United States: A Comprehensive Analysis of State-Level Disparities
Aviraag Vijaya Prakash¹, Vishwas Hosur Ravishankar², Aishwarya Sudheer¹ and Paramarajan Piranavan³, ¹Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, ²St Vincents Hospital, Worcester, MA, ³University of Kentucky, Division of Rheumatology, Lexington, KY
Background/Purpose: Rheumatoid Arthritis (RA) exhibits varied epidemiological patterns across states in the United States, influencing disability-adjusted life years (DALYs), incidence rates, prevalence, and mortality. This…
Abstract Number: 1959 • ACR Convergence 2024
A 3-arm, Randomized, Open-label, Parallel Active Controlled, Multicentre International Study to Compare the Response of Ultrasound-assessed Synovitis to Baricitinib, Alone and Combined with Methotrexate versus Etanercept in Rheumatoid Arthritis Patients
ESPERANZA NAREDO¹, Otto Olivas-Vergara², Pablo E. Borges², Sheila Recuero-Díaz², Fernando Saraiva³, Joana Martinho³, Filipa Costa³, Catarina Tenazinha³, Margarida Monteiro³, Ana Teresa Melo³, Ana Rodriguez-García⁴, Carlos A. Guillén-Astete⁵, Boris A. Blanco-Cáceres⁴, Alina L. Boteanu⁴, Antonio Mera-Varela⁶, Eva Pérez Pampín⁶, Yolanda López Golán⁶, Cristina Campos Fernández⁷, Jorge Juan Fragío Gíl⁷, roxana gonzalez mazarío⁷, Juan José De Agustín⁸, Gustavo Añez Sturchio⁹, Luis Coronel Tarancon⁸, Esther Vicente-rabaneda¹⁰, Santos Castañeda¹⁰, Irene Llorente-Cubas¹⁰, Maria S. Stoenoiu¹¹, NZEUSSEU TOUKAP Adrien¹², Ilaria Padovano¹³, Helene Gouze¹³, Ariane Leboime¹³, Maxime Breban¹⁴, Jaqueline Uson¹⁵, Virginia Villaverde¹⁶, Martina Steiner¹⁷, Cristina Vergara Dangond¹⁷, Maria Beatriz Paredes Romero¹⁷, Santiago Muñoz Fernández¹⁸, Carolina Pérez-García¹⁹, Juan Antonio Meraz-Ostiz¹⁹, Stephanie Finzel²⁰, Anna-Maria Kanne²¹, Aránzazu Mediero²², Carmen Herencia²³, Gabriel Herrero-Beaumont²⁴ and Raquel Largo²², ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, ⁴Rheumatology Department. Ramón y Cajal University Hospital, Madrid, Spain, ⁵Rheumatology Department. Ramon y Cajal University Hospital, Madrid, Spain, ⁶Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ⁷Department of Rheumatology. Hospital General Universitario de Valencia, Valencia, Spain, ⁸Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹Department of Rheumatology. Hospital Arnau de Vilanova, Lleida, Spain, ¹⁰Hospital Universitario de La Princesa, Madrid, Spain, ¹¹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹²Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, ¹³Departement of Rheumatology, Hopital Ambroise Paré, Boulogne-Billancourt, Spain, ¹⁴Departement of Rheumatology, Hopital Ambroise Paré, Departement of Rheumatology, Hopital Ambroise Paré, Spain, ¹⁵Department of Rheumatology, Hospital Universitario de Móstoles. University Rey Juan Carlos, Madrid, Spain, ¹⁶Department of Rheumatology, Hospital Universitario de Móstoles, Madrid, Spain, ¹⁷Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, ¹⁸Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain, ¹⁹Department of Rheumatology, Hospital del Mar of Barcelona, Barcelona, Spain, ²⁰Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, DE, Freiburg im Breisgau, Germany, ²¹Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany, ²²Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, Madrid, Spain, ²³Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, M, Spain, ²⁴Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: To demonstrate non-inferiority of the response of musculoskeletal ultrasound (MSKUS)-assessed synovitis to baricitinib, alone and plus MTX vs. etanercept plus MTX in patients with…
Abstract Number: 2169 • ACR Convergence 2024
Different Trajectories of Patient Reported Outcomes in Patients with RA in a Stable Phase of Disease – an Observational Study
Paul Studenic¹, Nadine Schwab², Günther Zauner², Thi Lan Vi Tran³ and Helga Lechner-Radner⁴, ¹Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria, Vienna, Austria, ²dwh GmbH, simulation services, Vienna, Austria & Institute of Information Systems Engineering, TU Wien, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria
Background/Purpose: In patients with rheumatoid arthritis (RA), we often see a disconnect between patient and evaluator perceived disease activity. In this study we aim to…
Abstract Number: 2226 • ACR Convergence 2024
Site-specific Differences in the Association of Non-vertebral Major Osteoporotic Fractures and Rheumatoid Arthritis
John Chen¹, Malini Chandra², Laura Carbone³, John Schousboe⁴, Elisha Garcia² and Joan Lo², ¹Kaiser Permanente Oakland Medical Center, Oakland, CA, ²Kaiser Permanente, Oakland, CA, ³Augusta University, Augusta, GA, ⁴University of Minnesota, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) and osteoporosis are both chronic, potentially debilitating conditions that frequently co-occur, affecting millions of people annually. Among those with osteoporosis, RA…
Abstract Number: 2242 • ACR Convergence 2024
A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis
Mohammad Movahedi¹, Elliot Hepworth², Angela Cesta³, Xiuying Li³, Claire Bombardier⁴ and Sibel Aydin⁵, and OBRI investogators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: COVID-19 infection frequently leads to a cytokine storm, which has successfully been treated with some immunomodulating therapies according to observational studies. Interestingly, treatments investigated…
Abstract Number: 2262 • ACR Convergence 2024
Window of Opportunity in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease with Abatacept. National Multicenter Study of 526 Patients
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Libe Ibarrola Paino³, Ivette Casafont-Sole⁴, Jesús Loarce⁵, Juan María Blanco Madrigal⁶, Santos Castañeda⁷, Rafaela Ortega-Castro⁸, Natalia Mena Vázquez⁹, Nuria Vegas Revenga¹⁰, Lucía Domínguez Casas¹¹, Cilia Peralta Ginés¹², Miriam Retuerto Guerrero¹³, Lorena Pérez Albadalejo¹⁴, Rubén López Sánchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez Viejo¹⁸, Gema Bonilla¹⁹, Olga Maíz Alonso²⁰, Carmen Carrasco-Cubero²¹, Marta Garijo Bufort²², Ana Urruticoechea Arana²³, Sergi Ordoñez²⁴, Carmen González Montagut²⁵, Andrea García-Valle²⁶, Juan Ramón De Dios²⁷, María Martín López²⁸, Tomás Vázquez Rodríguez²⁹, Delia Fernández-Lozano³⁰, Ignacio Brana Abascal³¹, Rafael Benito Melero-Gonzalez³², Emilio Giner³³, Virginia Ruiz-Esquide³⁴, Clara Ventin Rodriguez³⁵, Marina Rodriguez³⁶, Pablo Andújar-Brazal³⁷, Julia Fernandez Melon²³, Lilian M. López-Núñez³⁸, JOSE RAMON LAMUA RIAZUELO³⁹, Anna Pamies Corts⁴⁰, Carlos Fernández Díaz⁴¹, Javier Loricera⁴², Diego Ferrer⁴³ and Ricardo Blanco-Alonso⁴⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Rheumatology Division, Bisadoa Hospital, Bidasoa, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁹IBIMA, Málaga, Andalucia, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universitario San Agustín, Avilés, Spain, ¹²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Complejo Asistencial Universitario de León, Leon, Spain, ¹⁴Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹⁹H. Universitario La Paz, Madrid, Spain, ²⁰Hospital Universitario de Donosti, Donosti, Spain, ²¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Hospital Son Espases, Palma, Spain, ²⁴Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain, ²⁵Hospital Universitario de Valladolid, Valladolid, Spain, ²⁶Hospital General Río Carrión, Palencia, Spain, ²⁷Osakidetza, Vitoria, Spain, ²⁸General University Hospital of Ciudad Real, Ciudad de México, Spain, ²⁹Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³⁰Hospital Clínico Universitario de Valencia, Valencia, Spain, ³¹Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ³²CHU Ourense, O Carballino, Spain, ³³Hospital Royo Villanova, Teruel, Spain, ³⁴Hospital Clinic de Barcelona, Barcelona, Spain, ³⁵Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁶Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁷Hospital Universitario Doctor Peset, Valencia, Spain, ³⁸Hospital Universitari Son Llàtzer, Palma, Spain, ³⁹Hospital Universitario del Henares, Madrid, Spain, ⁴⁰Hospital Verge de la Cinta, Tortosa, TARRAGONA, Spain, ⁴¹Hospital Universitario Santa Lucía, Cartagena, Spain, ⁴²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴³Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD. Our objective…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].